Table 2.
The clinical characteristic between high CKS1B and low CKS1B group.
| Characteristic | Low expression of CKS1B | High expression of CKS1B | p |
|---|---|---|---|
| n | 89 | 89 | |
| T stage, n (%) | 0.145 | ||
| T1 | 4 (2.3%) | 3 (1.7%) | |
| T2 | 15 (8.5%) | 9 (5.1%) | |
| T3 | 66 (37.5%) | 76 (43.2%) | |
| T4 | 3 (1.7%) | 0 (0%) | |
| N stage, n (%) | 0.982 | ||
| N0 | 24 (13.9%) | 26 (15%) | |
| N1 | 61 (35.3%) | 62 (35.8%) | |
| M stage, n (%) | 1.000 | ||
| M0 | 38 (45.2%) | 41 (48.8%) | |
| M1 | 2 (2.4%) | 3 (3.6%) | |
| Pathologic stage, n (%) | 0.208 | ||
| Stage I | 13 (7.4%) | 8 (4.6%) | |
| Stage II | 69 (39.4%) | 77 (44%) | |
| Stage III | 3 (1.7%) | 0 (0%) | |
| Stage IV | 2 (1.1%) | 3 (1.7%) | |
| Radiation therapy, n (%) | 0.316 | ||
| No | 56 (34.4%) | 62 (38%) | |
| Yes | 26 (16%) | 19 (11.7%) | |
| Gender, n (%) | 0.292 | ||
| Female | 44 (24.7%) | 36 (20.2%) | |
| Male | 45 (25.3%) | 53 (29.8%) | |
| Age, n (%) | 0.764 | ||
| <=65 | 48 (27%) | 45 (25.3%) | |
| >65 | 41 (23%) | 44 (24.7%) | |
| Residual tumor, n (%) | 0.957 | ||
| R0 | 55 (33.5%) | 52 (31.7%) | |
| R1 | 26 (15.9%) | 26 (15.9%) | |
| R2 | 2 (1.2%) | 3 (1.8%) | |
| Histologic grade, n (%) | 0.006 | ||
| G1 | 22 (12.5%) | 9 (5.1%) | |
| G2 | 49 (27.8%) | 46 (26.1%) | |
| G3 | 16 (9.1%) | 32 (18.2%) | |
| G4 | 1 (0.6%) | 1 (0.6%) | |
| Alcohol history, n (%) | 0.658 | ||
| No | 34 (20.5%) | 31 (18.7%) | |
| Yes | 48 (28.9%) | 53 (31.9%) | |
| History of diabetes, n (%) | 0.215 | ||
| No | 48 (32.9%) | 60 (41.1%) | |
| Yes | 22 (15.1%) | 16 (11%) | |
| History of chronic pancreatitis, n (%) | 0.693 | ||
| No | 62 (44%) | 66 (46.8%) | |
| Yes | 5 (3.5%) | 8 (5.7%) | |
| Family history of cancer, n (%) | 0.700 | ||
| No | 22 (20%) | 25 (22.7%) | |
| Yes | 33 (30%) | 30 (27.3%) | |
| Age, mean ± SD | 64.16 ± 11.08 | 65.34 ± 10.54 | 0.468 |